BioGeneration Ventures
Arnoud is a venture partner with BGV and joined in 2018. He currently holds various positions in the management of BGV portfolio companies including VarmX and Staten Biotechnology.
After having spent 14 years in the Basel pharma industry, with his career ranging from research management in antibacterial R&D at Hoffmann-La Roche to business development and investor relations for Actelion, Arnoud moved back to the Netherlands in 2006, joining the Forbion portfolio antibody company PanGenetics as Chief Business Officer until it was sold to Abbott. He then was CBO of the hemostasis company Profibrix, which was acquired by The Medicines Company. He currently holds interim management positions in and provides consultancy services to several life science companies.
Arnoud has a MSc in chemistry and a PhD in Biochemistry from Groningen University.
This person is not in any offices
BioGeneration Ventures
BioGeneration Ventures (BGV) is a venture capital company, with a focus on early stage European biotech, medtech, and diagnostics companies. BGV has a strong track record of significant financial returns through investing in innovations in healthcare and providing the expertise to build world-class teams. The Company manages over €100 million of funds investing in areas where true scientific innovations, the unmet medical need, and the potential to demonstrate a significant proof of concept all come together.